DK3492455T3 - 1,2,4-triazoler som nukleare transportmodulatorer og anvendelse til behandling af specifikke former for cancer - Google Patents
1,2,4-triazoler som nukleare transportmodulatorer og anvendelse til behandling af specifikke former for cancer Download PDFInfo
- Publication number
- DK3492455T3 DK3492455T3 DK18202641.9T DK18202641T DK3492455T3 DK 3492455 T3 DK3492455 T3 DK 3492455T3 DK 18202641 T DK18202641 T DK 18202641T DK 3492455 T3 DK3492455 T3 DK 3492455T3
- Authority
- DK
- Denmark
- Prior art keywords
- triazoles
- cancer
- treatment
- specific forms
- nuclear transport
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361838172P | 2013-06-21 | 2013-06-21 | |
| EP14738998.5A EP3010892B8 (en) | 2013-06-21 | 2014-06-20 | 1,2,4-triazoles as nuclear transport modulators and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3492455T3 true DK3492455T3 (da) | 2023-08-14 |
Family
ID=51177201
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18202641.9T DK3492455T3 (da) | 2013-06-21 | 2014-06-20 | 1,2,4-triazoler som nukleare transportmodulatorer og anvendelse til behandling af specifikke former for cancer |
| DK14738998.5T DK3010892T3 (da) | 2013-06-21 | 2014-06-20 | 1,2,4-triazoler som kernetransportmodulatorer og anvendelser deraf |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14738998.5T DK3010892T3 (da) | 2013-06-21 | 2014-06-20 | 1,2,4-triazoler som kernetransportmodulatorer og anvendelser deraf |
Country Status (29)
| Country | Link |
|---|---|
| US (5) | US9738624B2 (da) |
| EP (2) | EP3010892B8 (da) |
| JP (2) | JP6730922B2 (da) |
| KR (2) | KR102322794B1 (da) |
| CN (3) | CN105339358B (da) |
| AU (5) | AU2014284168B2 (da) |
| BR (1) | BR112015032071B1 (da) |
| CA (1) | CA2915365C (da) |
| CY (1) | CY1122730T1 (da) |
| DK (2) | DK3492455T3 (da) |
| EA (1) | EA029743B1 (da) |
| ES (2) | ES2724275T3 (da) |
| HK (1) | HK1223936A1 (da) |
| HR (1) | HRP20190524T1 (da) |
| HU (1) | HUE042800T2 (da) |
| IL (2) | IL243099B (da) |
| LT (1) | LT3010892T (da) |
| ME (1) | ME03421B (da) |
| MX (1) | MX365939B (da) |
| PL (1) | PL3010892T3 (da) |
| PT (1) | PT3010892T (da) |
| RS (1) | RS58581B1 (da) |
| SG (1) | SG11201510036TA (da) |
| SI (1) | SI3010892T1 (da) |
| SM (1) | SMT201900184T1 (da) |
| TR (1) | TR201904455T4 (da) |
| UA (1) | UA119238C2 (da) |
| WO (1) | WO2014205389A1 (da) |
| ZA (1) | ZA201509015B (da) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011222531B2 (en) | 2010-03-05 | 2015-03-26 | Karyopharm Therapeutics, Inc. | Nuclear transport modulatiors and uses thereof |
| WO2012099807A1 (en) | 2011-01-17 | 2012-07-26 | Karyopharm Therapeutics, Inc. | Olefin containing nuclear transport modulators and uses thereof |
| CN103842340B (zh) | 2011-07-29 | 2017-09-22 | 卡尔约药物治疗公司 | 核转运调节剂及其应用 |
| RS56823B1 (sr) | 2011-07-29 | 2018-04-30 | Karyopharm Therapeutics Inc | Modulatori nukleusnog transporta koji sadrže hidrazid i njihove upotrebe |
| SMT201800686T1 (it) | 2012-05-09 | 2019-01-11 | Biogen Ma Inc | Modulatori di trasporto nucleare e loro usi |
| WO2014144772A1 (en) | 2013-03-15 | 2014-09-18 | Karyopharm Therapeutics Inc. | Methods of promoting wound healing using crm1 inhibitors |
| JP6730922B2 (ja) * | 2013-06-21 | 2020-07-29 | カリオファーム セラピューティクス，インコーポレイテッド | 核内輸送調節因子およびその使用 |
| WO2016025904A1 (en) | 2014-08-15 | 2016-02-18 | Karyopharm Therapeutics Inc. | Polymorphs of selinexor |
| WO2017117529A1 (en) * | 2015-12-31 | 2017-07-06 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
| US10709706B2 (en) * | 2015-12-31 | 2020-07-14 | Karopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
| WO2018050801A1 (en) * | 2016-09-16 | 2018-03-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of systemic mastocytosis |
| WO2018098472A1 (en) | 2016-11-28 | 2018-05-31 | Karyopharm Therapeutics Inc. | Crm1 inhibitors for treating epilepsy |
| WO2019137381A1 (en) | 2018-01-10 | 2019-07-18 | Xw Laboratories, Inc. | Prodrugs of ketamine, compositions and uses thereof |
| WO2019232724A1 (en) * | 2018-06-06 | 2019-12-12 | Xw Laboratories, Inc. | Compounds as nuclear transport modulators and uses thereof |
| WO2020051294A1 (en) * | 2018-09-07 | 2020-03-12 | Karyopharm Therapeutics Inc. | The combination of xpo1 inhibitors and second agents for the treatment of prostate cancer |
| WO2020092965A1 (en) * | 2018-11-01 | 2020-05-07 | Karyopharm Therapeutics Inc. | E2f1 as a biomarker for treatments using xpo1 inhibitors |
| MX2021006527A (es) | 2018-12-05 | 2021-07-21 | Scohia Pharma Inc | Compuesto macrociclico y su uso. |
| CN111606890A (zh) * | 2019-02-26 | 2020-09-01 | 微境生物医药科技(上海)有限公司 | 含丙烯酰基的核转运调节剂及其用途 |
| WO2021202745A1 (en) | 2020-03-31 | 2021-10-07 | Karyopharm Therapeutics Inc. | Treatment of covid-19 with a sine compound |
| CN113880803B (zh) * | 2020-07-03 | 2024-07-02 | 上海天慈国际药业有限公司 | 一种xpo-1抑制剂的制备方法 |
| WO2022089629A1 (zh) * | 2020-11-02 | 2022-05-05 | 江苏柯菲平医药股份有限公司 | 1,2,4-三氮唑衍生物及其制备方法和用途 |
| CN112294819B (zh) * | 2020-12-03 | 2021-12-14 | 中国人民解放军军事科学院军事医学研究院 | 一种炎症小体抑制剂及其应用 |
| CN113045550A (zh) * | 2021-03-12 | 2021-06-29 | 深圳济康医药科技有限公司 | 一种三氮唑类衍生物及其制备方法和应用 |
| CN117858873A (zh) | 2021-05-20 | 2024-04-09 | 卡尔约药物治疗公司 | 三唑基丙烯酰胺的杂芳基衍生物和结晶形式的合成方法 |
| CN113248474A (zh) * | 2021-05-24 | 2021-08-13 | 王能能 | 五元氮唑杂环衍生物及其制备方法和用途 |
| JP2024531204A (ja) | 2021-08-13 | 2024-08-29 | エックスダブリューファーマ リミテッド | ケタミン誘導体の医薬組成物及び経口剤形 |
| CN117940409A (zh) * | 2021-09-08 | 2024-04-26 | 南京明德新药研发有限公司 | 丙烯酰胺类化合物及其应用 |
| US20250002472A1 (en) * | 2021-10-29 | 2025-01-02 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Pyridyl-containing compound |
| WO2023134629A1 (zh) * | 2022-01-12 | 2023-07-20 | 上海海雁医药科技有限公司 | 核转运调节剂及其用途 |
| WO2024102477A1 (en) | 2022-11-11 | 2024-05-16 | Karyopharm Therapeutics Inc. | Crystalline forms of eltanexor and process for preparing same |
| TWI863768B (zh) * | 2023-12-21 | 2024-11-21 | 友達光電股份有限公司 | 顯示裝置 |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR840000529A (ko) | 1981-07-07 | 1984-02-25 | 콘스탄틴 루이스 클레멘트 | 인돌 유도체의 제조방법 |
| CS229934B2 (en) | 1981-07-07 | 1984-07-16 | Pfizer | Production method subst.indolylacryte acid derivative |
| US4778796A (en) | 1985-07-19 | 1988-10-18 | Dainippon Pharmaceutical Co., Ltd. | ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same |
| JP3111321B2 (ja) | 1990-02-23 | 2000-11-20 | 武田薬品工業株式会社 | 縮合チアゾール化合物 |
| IL97249A (en) | 1990-02-23 | 1995-01-24 | Takeda Chemical Industries Ltd | Compounds of 7,6,5,4-tetrahydrothiazole] B-5,4 [pyridine and compounds of 5,6-dihydro-H4-pyrrolo] D-3,2 [thiazole, their manufacture, and pharmaceutical compositions including or |
| US5541213A (en) | 1993-06-24 | 1996-07-30 | Eisai Co., Ltd. | Propenoic acid derivatives diazole propenoic acid compounds which have useful pharmaceutical utility |
| US5468353A (en) | 1994-05-05 | 1995-11-21 | Minnesota Mining And Manufacturing Company | Mist suppressant for solvent extraction metal electrowinning |
| AU4368996A (en) | 1994-11-23 | 1996-06-17 | Neurogen Corporation | Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands |
| US20030018025A1 (en) | 1995-06-07 | 2003-01-23 | Neurogen Corporation, Corporation Of The State Of Delaware | Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands |
| CA2229617A1 (en) | 1995-10-20 | 1997-05-01 | Dr. Karl Thomae Gmbh | 5-membered heterocycles, medicaments containing these compounds, their use and processes for their preparation |
| CA2250002C (en) | 1996-04-04 | 2008-03-25 | Shionogi & Co., Ltd. | Cephem compounds and drugs containing the compounds |
| AU736854B2 (en) | 1996-04-25 | 2001-08-02 | Nissan Chemical Industries Ltd. | Ethylene derivatives and pesticides containing said derivatives |
| JP4054992B2 (ja) | 1996-04-25 | 2008-03-05 | 日産化学工業株式会社 | エチレン誘導体および有害生物防除剤 |
| DE19624659A1 (de) | 1996-06-20 | 1998-01-08 | Klinge Co Chem Pharm Fab | Neue Pyridylalken- und Pyridylalkinsäureamide |
| US5994398A (en) | 1996-12-11 | 1999-11-30 | Elan Pharmaceuticals, Inc. | Arylsulfonamides as phospholipase A2 inhibitors |
| JP4416198B2 (ja) | 1997-12-19 | 2010-02-17 | 武田薬品工業株式会社 | アニリド誘導体、その製造法および用途 |
| WO1999050264A1 (fr) | 1998-03-30 | 1999-10-07 | Kyowa Hakko Kogyo Co., Ltd. | Derives de quinazoline |
| CO5271680A1 (es) | 2000-02-21 | 2003-04-30 | Smithkline Beecham Corp | Compuestos |
| DE60115279T2 (de) | 2000-09-29 | 2006-12-28 | Topotarget Uk Ltd., Abingdon | Carbaminsäurederivate enthaltend eine amidgruppe als hdac-inhibitoren |
| JP3795044B2 (ja) | 2001-09-14 | 2006-07-12 | メシルジーン、インコーポレイテッド | ヒストンデアセチラーゼの阻害剤 |
| WO2004037248A2 (en) | 2002-10-24 | 2004-05-06 | Carex Sa | Modulation of peroxisome proliferator activated receptors activity |
| DE10250743A1 (de) | 2002-10-31 | 2004-05-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
| JP4145230B2 (ja) | 2002-11-01 | 2008-09-03 | 武田薬品工業株式会社 | 神経障害の予防・治療剤 |
| CN1731994A (zh) | 2002-11-01 | 2006-02-08 | 武田药品工业株式会社 | 预防或治疗神经病的药剂 |
| CA2504941C (en) | 2002-11-08 | 2012-06-26 | Neurogen Corporation | 3-substituted-6-aryl pyridines |
| EP1599447A1 (en) | 2003-02-28 | 2005-11-30 | Galderma Research & Development, S.N.C. | Ligands that modulate lxr-type receptors |
| KR100966749B1 (ko) | 2004-05-26 | 2010-06-30 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 신나미드 화합물 |
| JPWO2006016637A1 (ja) | 2004-08-11 | 2008-05-01 | 杏林製薬株式会社 | 新規環状アミノ安息香酸誘導体 |
| WO2006019020A1 (ja) | 2004-08-16 | 2006-02-23 | Sankyo Company, Limited | 置換されたウレア化合物 |
| EP1849465A4 (en) | 2005-02-18 | 2008-12-24 | Takeda Pharmaceutical | AGENS TO CONTROL THE FUNCTION OF THE GPR34 RECEPTOR |
| DK1954684T3 (da) | 2005-11-15 | 2014-06-30 | Otsuka Pharma Co Ltd | Oxazol forbindelse og farmaceutisk sammensætning. |
| JP2007210929A (ja) | 2006-02-09 | 2007-08-23 | Sankyo Co Ltd | ウレア化合物を含有する医薬 |
| CA2643796A1 (en) | 2006-03-09 | 2007-09-13 | Eisai R & D Management Co., Ltd. | Polycyclic cinnamide derivatives |
| CN101466670B (zh) | 2006-04-07 | 2013-04-17 | 梅特希尔基因公司 | 组蛋白脱乙酰酶抑制剂 |
| EP2014652B1 (en) | 2006-04-18 | 2014-08-06 | Nippon Chemiphar Co., Ltd. | Activating agent for peroxisome proliferator activated receptor |
| US8653115B2 (en) | 2006-06-13 | 2014-02-18 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Heterocyclic non-nucleoside compounds, their preparation, pharmaceutical composition and their use as antiviral agents |
| AU2007277519B2 (en) | 2006-07-27 | 2011-12-22 | Amorepacific Corporation | Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same |
| US8273738B2 (en) | 2006-09-05 | 2012-09-25 | Kyowa Hakko Kirin Co., Ltd. | Imidazole derivatives |
| EP1942104A1 (en) | 2006-12-20 | 2008-07-09 | sanofi-aventis | Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals |
| EP1939180A1 (en) | 2006-12-20 | 2008-07-02 | sanofi-aventis | Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase |
| US7795457B2 (en) | 2007-02-26 | 2010-09-14 | Kosan Biosciences Incorporated | Carbamate compounds |
| EP2003118A1 (de) | 2007-06-13 | 2008-12-17 | Bayer Schering Pharma Aktiengesellschaft | Zimtsäurederivate als Modulatoren des EP2-Rezeptors |
| TW201011003A (en) | 2008-08-08 | 2010-03-16 | Synta Pharmaceuticals Corp | Triazole compounds that modulate HSP90 activity |
| MX2012000434A (es) | 2009-07-09 | 2012-04-11 | Crescendo Therapeutics Llc | Metodo de sanacion de herida y modulacion de cicatriz. |
| WO2011069039A1 (en) | 2009-12-04 | 2011-06-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hydrazone and diacyl hydrazine compounds and methods of use |
| AU2011222531B2 (en) | 2010-03-05 | 2015-03-26 | Karyopharm Therapeutics, Inc. | Nuclear transport modulatiors and uses thereof |
| WO2012099807A1 (en) * | 2011-01-17 | 2012-07-26 | Karyopharm Therapeutics, Inc. | Olefin containing nuclear transport modulators and uses thereof |
| RS56823B1 (sr) | 2011-07-29 | 2018-04-30 | Karyopharm Therapeutics Inc | Modulatori nukleusnog transporta koji sadrže hidrazid i njihove upotrebe |
| CN103842340B (zh) | 2011-07-29 | 2017-09-22 | 卡尔约药物治疗公司 | 核转运调节剂及其应用 |
| WO2013020024A2 (en) | 2011-08-03 | 2013-02-07 | Karyopharm Therapeutics, Inc. | Maleimide compounds and methods of treatment |
| SMT201800686T1 (it) | 2012-05-09 | 2019-01-11 | Biogen Ma Inc | Modulatori di trasporto nucleare e loro usi |
| WO2014152263A1 (en) | 2013-03-15 | 2014-09-25 | Karyopharm Therapeutics Inc. | Exo olefin-containing nuclear transport modulators and uses thereof |
| WO2014144772A1 (en) | 2013-03-15 | 2014-09-18 | Karyopharm Therapeutics Inc. | Methods of promoting wound healing using crm1 inhibitors |
| WO2014205393A1 (en) | 2013-06-21 | 2014-12-24 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
| JP6730922B2 (ja) | 2013-06-21 | 2020-07-29 | カリオファーム セラピューティクス，インコーポレイテッド | 核内輸送調節因子およびその使用 |
| WO2015073908A1 (en) | 2013-11-15 | 2015-05-21 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Method for selecting cancer treatment regimen |
| US9828373B2 (en) | 2014-07-26 | 2017-11-28 | Sunshine Lake Pharma Co., Ltd. | 2-amino-pyrido[2,3-D]pyrimidin-7(8H)-one derivatives as CDK inhibitors and uses thereof |
| WO2016025904A1 (en) | 2014-08-15 | 2016-02-18 | Karyopharm Therapeutics Inc. | Polymorphs of selinexor |
| US10709706B2 (en) | 2015-12-31 | 2020-07-14 | Karopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
| WO2017117529A1 (en) | 2015-12-31 | 2017-07-06 | Karyopharm Therapeutics Inc. | Nuclear transport modulators and uses thereof |
| US11034675B2 (en) | 2016-01-08 | 2021-06-15 | Dr. Reddy's Laboratories Limited | Solid forms of Selinexor and process for their preparation |
| WO2018098472A1 (en) | 2016-11-28 | 2018-05-31 | Karyopharm Therapeutics Inc. | Crm1 inhibitors for treating epilepsy |
| EP3565813A1 (en) | 2017-01-05 | 2019-11-13 | Watson Laboratories, Inc. | Novel crystalline forms of selinexor and process for their preparation |
| EP3808742A1 (en) | 2019-10-16 | 2021-04-21 | Sandoz AG | Polymorph of selinexor |
| WO2021111103A1 (en) | 2019-12-06 | 2021-06-10 | Bae Systems Plc | Light source |
| US20230391754A1 (en) | 2020-10-21 | 2023-12-07 | Karyopharm Therapeutics Inc. | Crystalline form of selinexor |
-
2014
- 2014-06-20 JP JP2016521862A patent/JP6730922B2/ja active Active
- 2014-06-20 DK DK18202641.9T patent/DK3492455T3/da active
- 2014-06-20 LT LTEP14738998.5T patent/LT3010892T/lt unknown
- 2014-06-20 CN CN201480035555.8A patent/CN105339358B/zh active Active
- 2014-06-20 US US14/900,469 patent/US9738624B2/en active Active
- 2014-06-20 MX MX2015016983A patent/MX365939B/es active IP Right Grant
- 2014-06-20 WO PCT/US2014/043479 patent/WO2014205389A1/en active Application Filing
- 2014-06-20 SG SG11201510036TA patent/SG11201510036TA/en unknown
- 2014-06-20 EP EP14738998.5A patent/EP3010892B8/en active Active
- 2014-06-20 DK DK14738998.5T patent/DK3010892T3/da active
- 2014-06-20 EP EP18202641.9A patent/EP3492455B1/en active Active
- 2014-06-20 CA CA2915365A patent/CA2915365C/en active Active
- 2014-06-20 KR KR1020167001020A patent/KR102322794B1/ko active Active
- 2014-06-20 PT PT14738998T patent/PT3010892T/pt unknown
- 2014-06-20 ES ES14738998T patent/ES2724275T3/es active Active
- 2014-06-20 ME MEP-2019-88A patent/ME03421B/me unknown
- 2014-06-20 SI SI201431142T patent/SI3010892T1/sl unknown
- 2014-06-20 EA EA201690044A patent/EA029743B1/ru unknown
- 2014-06-20 AU AU2014284168A patent/AU2014284168B2/en active Active
- 2014-06-20 UA UAA201600474A patent/UA119238C2/uk unknown
- 2014-06-20 BR BR112015032071-6A patent/BR112015032071B1/pt active IP Right Grant
- 2014-06-20 RS RS20190400A patent/RS58581B1/sr unknown
- 2014-06-20 ES ES18202641T patent/ES2952774T3/es active Active
- 2014-06-20 CN CN201910393112.0A patent/CN110183422B/zh active Active
- 2014-06-20 TR TR2019/04455T patent/TR201904455T4/tr unknown
- 2014-06-20 HU HUE14738998A patent/HUE042800T2/hu unknown
- 2014-06-20 CN CN201910389947.9A patent/CN110386919B/zh active Active
- 2014-06-20 SM SM20190184T patent/SMT201900184T1/it unknown
- 2014-06-20 KR KR1020217035649A patent/KR102545732B1/ko active Active
- 2014-06-20 PL PL14738998T patent/PL3010892T3/pl unknown
-
2015
- 2015-12-10 ZA ZA2015/09015A patent/ZA201509015B/en unknown
- 2015-12-14 IL IL243099A patent/IL243099B/en active IP Right Grant
-
2016
- 2016-10-25 HK HK16112272.6A patent/HK1223936A1/zh unknown
-
2017
- 2017-07-17 US US15/651,856 patent/US10407405B2/en active Active
-
2018
- 2018-09-05 IL IL261612A patent/IL261612A/en unknown
-
2019
- 2019-01-10 AU AU2019200147A patent/AU2019200147A1/en not_active Abandoned
- 2019-03-18 HR HRP20190524TT patent/HRP20190524T1/hr unknown
- 2019-03-26 CY CY20191100349T patent/CY1122730T1/el unknown
- 2019-07-23 US US16/519,955 patent/US11124493B2/en active Active
-
2020
- 2020-07-03 JP JP2020115772A patent/JP7061161B2/ja active Active
- 2020-11-23 AU AU2020277088A patent/AU2020277088B2/en active Active
-
2021
- 2021-08-23 US US17/409,150 patent/US11945794B2/en active Active
-
2022
- 2022-12-06 AU AU2022283662A patent/AU2022283662A1/en not_active Abandoned
-
2024
- 2024-02-23 US US18/586,019 patent/US20250059158A1/en active Pending
- 2024-07-12 AU AU2024204818A patent/AU2024204818A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3492455T3 (da) | 1,2,4-triazoler som nukleare transportmodulatorer og anvendelse til behandling af specifikke former for cancer | |
| IL247458A0 (en) | Methods and compositions for increasing a t-effector cell to regulatory t cell ratio | |
| DK3256468T3 (da) | Tricykliske forbindelser og anvendelser deraf i lægemidler | |
| HK1219734A1 (zh) | 抑制劑和使用所述抑制劑的治療方法 | |
| HUE055554T2 (hu) | 19-nor-C3,3-Diszubsztituált C21-N-pirazolil szteroid terápiában történõ alkalmazásra | |
| DK3508502T5 (da) | Kombination af anti-lag-3-antistoffer og anti-pd-1-antistoffer til behandling af tumorer | |
| DK3044234T3 (da) | Anti-PD1-antistoffer og anvendelse deraf som terapeutika og diagnostika | |
| SG11201704226PA (en) | Materials, components, and methods for use with extreme ultraviolet radiation in lithography and other applications | |
| HUE037250T2 (hu) | Duokarmicin ADC-k (antitest-hatóanyag konjugátumok) húgyhólyagrák kezelésében történõ alkalmazásra | |
| EP2944323A4 (en) | MEANS FOR THE TREATMENT OF TUMORS, USE AND METHOD THEREFOR | |
| DK4119569T3 (da) | Konjugerede antisense-forbindelser til anvendelse i behandling | |
| DK3374497T3 (da) | Modificerede makrofager til anvendelse i behandlingen af kræft | |
| GB201511382D0 (en) | Novel compounds and their use in therapy | |
| DK3606926T3 (da) | Heteroaromatiske forbindelser anvendelige i terapi | |
| DK3003363T3 (da) | Immunogen sammensætning til anvendelse i terapi | |
| DK3434276T3 (da) | Fremgangsmåde og farmaceutisk sammensætning til anvendelse i behandlingen af kræft | |
| DK3383872T3 (da) | 1,3,4-thiadiazolforbindelser og anvendelse deraf i cancerbehandling | |
| DK2951208T3 (da) | Anti-cd83 antistoffer og anvendelse deraf | |
| DK3071192T3 (da) | Curcuphenolforbindelse til anvendelse i behandling af cancer | |
| DK2964248T3 (da) | Behandling af og profylakse for stråledermatitis | |
| PT3406258T (pt) | Medicamento para utilização no tratamento de gota | |
| DK3383871T3 (da) | 1,3,4-thiadiazolforbindelser og anvendelse deraf i behandling af cancer | |
| DK3380468T3 (da) | Bis-pyridazinforbindelser og anvendelse heraf i behandling af cancer | |
| DK3297979T3 (da) | Forbindelser og fremgangsmåder til at modulere serotoninreceptorer i periferien | |
| DK3081560T3 (da) | Taxanforbindelser, fremgangsmåde til fremstilling deraf og anvendelse deraf |